Trial Profile
Safety and efficacy of (Absorb) Bioresorbable everolimus-eluting Vascular Scaffold in subjects with percutaneous chronic total occlusion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CTO ABSORB pilot
- 19 Dec 2015 New trial record